First-Line Treatment of Mycosis Fungoides at Clinical Stage IIB (T3, Skin Tumours ≥1 cm)

Mycosis fungoides reaching clinical stage IIB is characterised by the development of one or more cutaneous tumours of at least 1 cm (T3 disease), a threshold that marks progression beyond patch and plaque stages and calls for a specific first-line management strategy.

Clinical scenario: Mycosis fungoides, clinical stage IIB — T3 classification with one or more skin tumours measuring ≥1 cm. This staging is the defining feature that shapes treatment selection at this line of therapy.

First-Line Approach

First-line management at stage IIB draws from several therapeutically equivalent options. These span both systemic agents and skin-directed modalities, with the applicable choice dependent on disease characteristics such as CD30 expression status and individual clinical context.

The full decision algorithm, complete option list, and clinical criteria for selecting among equivalent approaches are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Recommendations for first-line treatment of MF stage IIB.

DOI: 10.1016/j.ejca.2023.113343

View source ↗